Ken Griffin Relay Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,700 shares of RLAY stock, worth $11,033. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,700
Previous 4,200
59.52%
Holding current value
$11,033
Previous $34,000
67.65%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding RLAY
# of Institutions
182Shares Held
126MCall Options Held
1.7KPut Options Held
18K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$181 Million1.68% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$76 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$68.4 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY8.45MShares$54.8 Million4.77% of portfolio
-
Bellevue Group Ag Kuesnacht, V86.38MShares$41.4 Million0.7% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $780M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...